These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33074106)

  • 1. Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A.
    Franco A; Dang X; Walton EK; Ho JN; Zablocka B; Ly C; Miller TM; Baloh RH; Shy ME; Yoo AS; Dorn GW
    Elife; 2020 Oct; 9():. PubMed ID: 33074106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial Dysfunction and Pharmacodynamics of Mitofusin Activation in Murine Charcot-Marie-Tooth Disease Type 2A.
    Franco A; Dang X; Zhang L; Molinoff PB; Dorn GW
    J Pharmacol Exp Ther; 2022 Nov; 383(2):137-148. PubMed ID: 36507849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human mitofusin 2 mutation can cause mitophagic cardiomyopathy.
    Franco A; Li J; Kelly DP; Hershberger RE; Marian AJ; Lewis RM; Song M; Dang X; Schmidt AD; Mathyer ME; Edwards JR; Strong CG; Dorn GW
    Elife; 2023 Nov; 12():. PubMed ID: 37910431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensory-Motor Neuropathy in Mfn2 T105M Knock-in Mice and Its Reversal by a Novel Piperine-Derived Mitofusin Activator.
    Weigele J; Zhang L; Franco A; Cartier E; Dorn GW
    J Pharmacol Exp Ther; 2024 Oct; 391(2):361-374. PubMed ID: 39284622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.
    Rocha AG; Franco A; Krezel AM; Rumsey JM; Alberti JM; Knight WC; Biris N; Zacharioudakis E; Janetka JW; Baloh RH; Kitsis RN; Mochly-Rosen D; Townsend RR; Gavathiotis E; Dorn GW
    Science; 2018 Apr; 360(6386):336-341. PubMed ID: 29674596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot-Marie-Tooth type 2A.
    Detmer SA; Vande Velde C; Cleveland DW; Chan DC
    Hum Mol Genet; 2008 Feb; 17(3):367-75. PubMed ID: 17959936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial Phenotypes in Genetically Diverse Neurodegenerative Diseases and Their Response to Mitofusin Activation.
    Dang X; Walton EK; Zablocka B; Baloh RH; Shy ME; Dorn GW
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mutation associated with CMT2A neuropathy causes defects in Fzo1 GTP hydrolysis, ubiquitylation, and protein turnover.
    Amiott EA; Cohen MM; Saint-Georges Y; Weissman AM; Shaw JM
    Mol Biol Cell; 2009 Dec; 20(23):5026-35. PubMed ID: 19812251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A.
    Cartoni R; Arnaud E; Médard JJ; Poirot O; Courvoisier DS; Chrast R; Martinou JC
    Brain; 2010 May; 133(Pt 5):1460-9. PubMed ID: 20418531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations.
    Detmer SA; Chan DC
    J Cell Biol; 2007 Feb; 176(4):405-14. PubMed ID: 17296794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitofusin gain and loss of function drive pathogenesis in
    El Fissi N; Rojo M; Aouane A; Karatas E; Poliacikova G; David C; Royet J; Rival T
    EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29898954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mfn2
    Zhang Y; Ma L; Wang Z; Gao C; Yang L; Li M; Tang X; Yuan H; Pang D; Ouyang H
    Int J Biol Macromol; 2024 Oct; 278(Pt 1):134673. PubMed ID: 39142491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cohort study of Han Chinese MFN2-related Charcot-Marie-Tooth 2A.
    Lv H; Wang L; Zhang W; Wang Z; Zuo Y; Liu J; Yuan Y
    J Neurol Sci; 2015 Nov; 358(1-2):153-7. PubMed ID: 26382835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations.
    Amiott EA; Lott P; Soto J; Kang PB; McCaffery JM; DiMauro S; Abel ED; Flanigan KM; Lawson VH; Shaw JM
    Exp Neurol; 2008 May; 211(1):115-27. PubMed ID: 18316077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A.
    Cartoni R; Martinou JC
    Exp Neurol; 2009 Aug; 218(2):268-73. PubMed ID: 19427854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-Marie-Tooth type 2A.
    Rizzo F; Bono S; Ruepp MD; Salani S; Ottoboni L; Abati E; Melzi V; Cordiglieri C; Pagliarani S; De Gioia R; Anastasia A; Taiana M; Garbellini M; Lodato S; Kunderfranco P; Cazzato D; Cartelli D; Lonati C; Bresolin N; Comi G; Nizzardo M; Corti S
    Cell Mol Life Sci; 2023 Nov; 80(12):373. PubMed ID: 38007410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioenergetic defect associated with mKATP channel opening in a mouse model carrying a mitofusin 2 mutation.
    Guillet V; Gueguen N; Cartoni R; Chevrollier A; Desquiret V; Angebault C; Amati-Bonneau P; Procaccio V; Bonneau D; Martinou JC; Reynier P
    FASEB J; 2011 May; 25(5):1618-27. PubMed ID: 21285398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Charcot-Marie-Tooth type 2A in vivo models: Current updates.
    Abati E; Rizzuti M; Anastasia A; Comi GP; Corti S; Rizzo F
    J Cell Mol Med; 2024 May; 28(9):e18293. PubMed ID: 38722298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A SARM1-mitochondrial feedback loop drives neuropathogenesis in a Charcot-Marie-Tooth disease type 2A rat model.
    Sato-Yamada Y; Strickland A; Sasaki Y; Bloom J; DiAntonio A; Milbrandt J
    J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36287202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model.
    Zhou Y; Carmona S; Muhammad AKMG; Bell S; Landeros J; Vazquez M; Ho R; Franco A; Lu B; Dorn GW; Wang S; Lutz CM; Baloh RH
    J Clin Invest; 2019 Mar; 129(4):1756-1771. PubMed ID: 30882371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.